PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us

Are AI-generated materials legally privileged? United States v. Heppner

  • Sector: Patent law
  • 13th May 2026
Legal privilege ensures that you can share sensitive information with your lawyers without fear of it being used against you in court. This protection is critical in all fields of law. In patent law, without the assurance of secrecy, the ability of a patentee or a defendant to receive candid advice would be severely diminished.
 

Originally posted on IPKat

Now, with the growing ubiquity of AI in the legal industry, much attention has been given to the recent case of United States v. Heppner. The court was asked whether communications about a legal case with a publicly available AI platform were protected by attorney-client privilege or the similar work product doctrine. The judge’s answer was a clear “no”. Other than the obvious (don’t put confidential information into public AI tools!), what lessons can we take from this about the safe use of AI in the patent industry?

AI and legal privilege: United States v. Heppner

Last year, Mr Heppner was indicted on federal charges including securities fraud. Following a grand jury subpoena and learning he was a target, Heppner, acting on his own without instruction from legal counsel, used Claude to prepare documents outlining his defence strategies. When Mr Heppner was subsequently arrested in November, federal agents executed a search warrant and seized electronic devices from his home that contained approximately thirty-one of these AI-generated documents. Heppner and his counsel asserted privilege, but the government moved to review the materials.

Judge Rakoff ruled that the AI-generated materials were not protected by attorney-client privilege. In a written memorandum, the judge explained that the AI tool failed the standard three-part test for privilege. Firstly, there was no attorney-client relationship because an AI is not a licensed professional bound by fiduciary duties or subject to professional discipline. Interestingly, in a completely unrelated case, ChatGPT has just been sued for providing legal advice without a licence. Secondly, the court found that there was no confidentiality in place as the Anthropic privacy policy for Claude discloses that they collect user inputs, trains on user data, and may disclose data to third parties including government authorities. 

Finally, the judge noted that Mr Heppner did not communicate with Claude “for the purpose of obtaining legal advice”, e.g. under the direction of counsel. Interestingly, the judge observed that “[h]ad counsel directed Heppner to use Claude, Claude might arguably be said to have functioned in a manner akin to a highly trained professional who may act as a lawyer’s agent within the protection of the attorney-client privilege”. However, because the Claude platform includes a disclaimer stating it cannot provide formal legal advice, Mr Heppner could not be considered to be seeking legal advice. As the judge also noted, “when the Government asked Claude whether it could give legal advice, it responded that ‘I’m not a lawyer and can’t provide formal legal advice or recommendations’ and went on to recommend that a user ‘should consult with a qualified attorney who can properly assess your specific circumstances'”.

Given these three circumstances, it was clear to the judge that legal privilege did not apply. 

The limits of protection (Work product doctrine)

The judge’s reasoning on privilege noted that “some commentators have argued that whether Claude is an attorney is irrelevant because a user’s AI inputs, rather than being communications, are more akin to the use of other Internet-based software, such as cloud-based word processing applications”. However, that judge noted that “the use of such applications is not intrinsically privileged in any case”. This leads to a second protection in US law, the work product doctrine (WPD). The WPD serves as a complementary shield to legal privilege by protecting materials prepared in anticipation of litigation. In the context of patents, this includes documents such as infringement analyses or validity opinions created by or for patent attorneys. This doctrine ensures that an attorney can prepare a case thoroughly without the risk of their internal thoughts and strategies being handed over to the other side.

In the Heppner case, the court also rejected the application of the WPD. Judge Rakoff noted again that the documents were created by Heppner independently in coordination with Claude rather than at the direction or supervision of counsel. Furthermore, simply sharing non-privileged communications with an attorney after they are created did not retroactively convert them into privileged ones. The WPD, the judge emphasised, is to protect the mental processes of lawyers, and “generally does not shield from discovery documents that were not prepared by the attorneys themselves, or their agents”. 

Analysis

The existence or otherwise of legal privilege or protection under the work product doctrine can be critical to the outcome of patent litigation in the US, and in particular the awarding of triple damages. In the US, a court may increase damages up to three times the amount found or assessed in cases of wilful infringement, i.e. where it can be proved that the defendant knew about the patent and that they were infringing. 

However, it is important to understand the limitations of the applicability of the decision in Heppner. Notably, the court did not request or receive any documents from Anthropic. There was no need, as Mr Heppner had saved the advice locally on his own device. Nonetheless, the court’s reasoning regarding the privacy policy made it clear that subpoenaing the AI company directly would have been a viable path. Indeed, this kind of document discovery is not merely a theoretical concern. Last year, DHS investigators obtained prompt-level data from OpenAI through a warrant in a criminal investigation. Furthermore, in copyright litigation between the New York Times and OpenAI, the court compelled the production of twenty million anonymized chat logs. It is clear that AI companies may therefore be forced to hand over stored user data during negotiations or under legal compulsion. You cannot assume that anything submitted into a publicly available AI is or will remain confidential. 

The fact that Mr Heppner was using a version of Claude lacking any confidentiality restrictions was clearly highly influential to the outcome of the case. These publicly available tools are different to the enterprise-grade versions, provided under conditions of confidentiality, with no training on user data and no data retention agreements in place (Evolve insights). However, regardless of even these provisions, the saved outputs of AI tools may be a different matter. Caution must therefore be taken with the use of third-party software providers and software that may store your inputs, outputs and chat history, even when these are stored locally or provided under conditions of confidentiality. Documented opinions about the validity and potential infringement risk of patents without a clear client-attorney relationship are always fraught with risk, regardless of who or what generated them. 

Author: Rose Hughes

Rose is a biotech and pharmaceutical patent specialist with over a decade of experience in intellectual property. Rose is a patent attorney at Evolve, where she leverages our unique fractional in-house model to provide clients with deep patent law expertise combined with the strategic commercial oversight typically associated with senior in-house counsel.

With a PhD in Immunology from UCL, Rose applies her technical background to complex innovations in biologics, cell and gene therapies, and the rapidly emerging field of AI-assisted drug development. Previously, Rose held the role of Director. Patents at AstraZeneca, where she was responsible for global IP portfolios and IP strategy at every stage of the pharmaceutical pipeline, from platform development and on-market commercialization to SPCs and patent term extensions.

A recognized thought leader in the field, Rose has been a regular contributor to IPKat since 2018, offering practical insights into European patent law developments. She is also a frequent speaker on the epi podcast, a guest lecturer for the Brunel University IP law Postgrad Certificate, and a contributing author to published books A User’s Guide to Intellectual Property in Life Sciences (2021) and Developments and Directions in Intellectual Property Law (2023).

Related insights...

Is AI software for IP just expensive wrapping paper?

  • 14th May 2026
At the last count, there were more than seventy companies offering AI-assisted IP software solutions. Most of these companies are less than two years old.

The future of the patent profession: Are we looking into an AI abyss?

  • 8th May 2026
AI presents a huge dilemma for patent attorneys. There is no doubt that AI will have a dramatic impact on the profession and the business model that many firms have relied on for decades.

Use of AI in the patent industry: Are you behind the wheel or waiting for the bus?

  • 1st May 2026
It took a global pandemic to move some patent firms away from paper files. Today, it seems that patent attorneys are finally entering modernity with the growing adoption in the industry of automation tools for patent drafting and prosecution case management. Interestingly, much of this is being sold and promoted as “AI”, despite much of…

Use of AI in the patent industry: The spectre of hallucination

  • 10th October 2025
What are the risks of AI hallucinations for the patent industry?

Use of AI in the patent industry: Solving the confidentiality problem

  • 10th October 2025
How can patent attorneys ensure client confidentiality when using AI software for patents.

Evolve AI: Building AI tools for IP that are expert-led and pharma-specific

  • 2nd October 2025
We believe that the value of AI for our profession lies in developing highly specialised tools that build upon and incorporate domain-specific attorney expertise.

Is it time for patent offices to enter the bioinformatic age?

  • 13th June 2025
In a world in which incalculable amounts of sophisticated sequence data is freely available, are the clunky processes necessary to input patent sequence data really fit-for-purpose?

An LLM is not (yet) a person skilled in the art (T 1193/23)

  • 20th May 2025
The EPO clarifies that an LLM interpretation of a technical term in a patent is not yet evidence of how a skilled person would interpret the term.

OpenAI’s large language model (LLM) patents

  • 29th April 2025
For tech innovators seeking to understand evolving intellectual property strategies, OpenAI’s recent pivot offers essential guidance: far from relying solely on trade secrets, the AI leader is now aggressively pursuing and accelerating patent grants, signaling a significant shift.

“Using AI tools to help assess inventive step”: A response to the CIPA journal article

  • 16th July 2024
This post is based on a previous article on IPKat. The cover article of the May 2024 edition of the CIPA Journal proposed a new test for inventive step using AI. The article was inspired by the EPO’s AI assisted search tool, AI-PreSearch. The CIPA journal article proposes to use an AI derived measurement of semantic similarity between the…
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

Subscribe

Contact Us